The present invention relates to the use of ruthenium(II) complexes for preparing a medicinal product for treating cancer, particularly cancer comprising cancer stem cells. Said ruthenium complexes are capable of selectively metallating guanine quadruplexes, thus resulting in increased expression of the c-MYC oncogene. This increase in the proportion of c-MYC may promote the differentiation of cancer stem cells.
